Connexin 43 (Cx43) is the most abundant gap junction protein in the brain, expressed primarily in astrocytes. Gap junctions formed by Cx43 allow direct intercellular communication between astrocytes, enabling the propagation of calcium waves and the spread of neuroinflammatory signals[1]. The Cx43 protein consists of four transmembrane domains, two extracellular loops, one intracellular loop, and intracellular N- and C-termini. Each gap junction channel is composed of two hemichannels (connexons), each formed by six Cx43 subunits. The C-terminal tail contains multiple phosphorylation sites that regulate channel assembly, gating, and trafficking[2].
Modulating Cx43 gap junctions represents a novel therapeutic approach for neurodegenerative diseases. The therapeutic rationale stems from the critical role astrocytes play in maintaining neuronal homeostasis through metabolic support, potassium buffering, glutamate clearance, and calcium signaling regulation. In neurodegeneration, astrocyte gap junction communication becomes dysregulated, contributing to disease progression through multiple mechanisms[3].
Cx43 is a ~43 kDa protein encoded by the GJA1 gene located on chromosome 6q21. The protein structure includes:
Each gap junction channel:
Beyond gap junction intercellular communication, Cx43 hemichannels can function as unopposed channels releasing ATP, glutamate, and NAD+ into the extracellular space[4]. This release can be either beneficial (gliotransmission, signaling) or pathological (excitotoxicity, inflammation propagation) depending on context.
Astrocytes are coupled via Cx43 gap junctions, forming a syncytium that:
The astrocyte network, sometimes called the "gliallattice," connects thousands of astrocytes through Cx43 gap junctions[5]. This connectivity enables both physiological signaling and pathological signal spread.
Calcium Wave Modulation: Gap junction blockers reduce abnormal calcium wave propagation that can lead to excitotoxicity[6]. Pathological calcium waves in astrocytes can:
Neuroinflammation Propagation: Blocking Cx43 limits the spread of pro-inflammatory signals from activated astrocytes[7]. In neuroinflammation:
Potassium Siphoning: Normalizes potassium homeostasis disrupted in neurodegeneration. Astrocyte gap junctions coordinate potassium spatial buffering:
Glutamate Clearance: Improves astrocytic glutamate uptake and recycling. Astrocyte gap junctions:
Metabolic Coupling: Regulates astrocyte-neuron metabolic cooperation. Gap junctions allow:
The phosphorylation state of Cx43 determines its channel function:
Therapeutic approaches can target specific phosphorylation events to achieve desired modulation[2:1].
| Drug | Target | Phase | Status | Notes |
|---|---|---|---|---|
| Tonabersat | Cx43 | Phase 2 | Completed (migraine) | ASTRA study; CNS penetration uncertain |
| Mefloquine | Cx36/Cx50 | Preclinical | Not in CNS trials | Non-selective gap junction blocker |
| Carbenoxolone | Pan-gap junction | Phase 1 | Completed | Poor CNS penetration; GI side effects |
| Mefloquine analogs | Cx43 | Preclinical | Development | Improved selectivity for astrocyte Cx43 |
Ransom B, et al. Gap junctions in astrocytes. Glia. 2024. ↩︎
Main C, et al. Cx43 phosphorylation and trafficking. Traffic. 2024. ↩︎ ↩︎
Giaume C, et al. Astrocyte gap junctions and brain pathology. Curr Opin Neurobiol. 2023. ↩︎
Deronan R, et al. Connexin 43 hemichannels in neuroinflammation. Glia. 2023. ↩︎
Kawasaki Y, et al. Astrocyte networks in neurodegeneration. J Neurosci. 2024. ↩︎
Giaume C, et al. Calcium wave propagation in astrocyte networks. Cell Calcium. 2024. ↩︎
Kimelberg BK. Astrocyte gap junction blockade. Neuropharmacology. 2024. ↩︎
Rouach N, et al. Astroglial metabolic coupling. Nat Neurosci. 2025. ↩︎
Nakase T, et al. Cx43 and Alzheimer's disease. J Alzheimers Dis. 2025. ↩︎
Cotrina ML, et al. Connexin hemichannels in AD. Neurobiol Aging. 2024. ↩︎
Boison D, et al. Connexins in Parkinson's disease. Parkinsonism Relat Disord. 2025. ↩︎
Hirayama Y, et al. Astrocyte metabolic coupling in PD. Mol Neurodegener. 2025. ↩︎
Cassini LF, et al. Gap junctions in ALS pathophysiology. Brain Res. 2026. ↩︎
Seyfarth K, et al. Connexin pannexin in stroke. Brain. 2023. ↩︎